Trial Profile
An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Apr 2021
Price :
$35
*
At a glance
- Drugs F 652 (Primary)
- Indications Alcoholic hepatitis
- Focus Adverse reactions
- Acronyms TREAT 008
- 27 Nov 2019 Results assessing safety and efficacy signals of F-652 in patients with moderate and severe Alcoholic Hepatitis published in the Hepatology
- 14 Aug 2018 Status changed from recruiting to completed.
- 29 Apr 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.